viewAmryt Pharma PLC

Amryt Pharma: Cantor Fitzgerald backs orphan drug group for NASDAQ success

The broker kicked off its US coverage of the stock with a US$45 a share valuation

Amryt Pharma PLC -

Wednesday was a red-letter day for Amryt Pharma PLC (LON:AMYT, NASDAQ:AMYT), which listed on the NASDAQ exchange for high growth companies.

It did so with the resounding backing of Cantor Fitzgerald, which kicked off its US coverage of the stock with a US$45 a share valuation. To put the 12-month target into perspective, Amryt closed at US$11.25.

The group sells and develops orphan drugs used to treat rare diseases and has two products on the market.

Transformational was its acquisition of Aegerion Pharmaceuticals, which gave it full control of the Lojuxta cholesterol treatment.

The key kickers for the business, according to Cantor, include the continued growth of the approved products; phase III data later this year from AP101 for a rare skin condition; and updates from two separate Lojuxta trials.

On the US listing chief executive, Joe Wiley, speaking to Proactive’s Andrew Scott, said it would “enhance the value of its equity on both sides of the Atlantic” as well as broaden Amryt’s analyst coverage.

“With nearly 70% of our shareholders based in North America, listing on NASDAQ is an important part of our shareholder engagement and development plans,” he told investors yesterday.

“Furthermore, we believe our NASDAQ listing will significantly assist our efforts to drive value for all our stakeholders.”

Quick facts: Amryt Pharma PLC

Price: 198 GBX

Market: AIM
Market Cap: £322.35 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...


Amryt Pharma reports record Q3 2020 results, delivering 19% year on year growth

Amryt Pharma's LON:AMYT) Joe Wiley talks to Proactive New York's Christine Corrado about their latest record Q3 2020 Results. The results have lead to the full year guidance being raised which Wiley puts down to two launched commercial assents, metreleptin and lomitapide. Wiley talks...

3 weeks, 4 days ago

2 min read